SBPH Spring Bank Pharmaceuticals Inc gains 30% Mar 29, 2021

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that are design to target and modulate the activity of specific proteins implicated in various disease states. The company's lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops SMNH product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers; and SB 9400, SB 9941 and SB 9946 preclinical product candidates for viral diseases. The company has an agreement with Arrowhead Pharmaceuticals, Inc. to collaborate on the study of the combined use of SB 9200 and small interfering ribonucleic acid product pipeline for the treatment of chronic hepatitis B virus (HBV); and Arbutus Biopharma Corporation to collaborate on the preclinical study of the combined use of SB 9200 and AB-423, a capsid assembly inhibitor for the treatment of chronic HBV. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.http://www.priceseries.com/trade/SBPH-Spring-Bank-Pharmaceuticals-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2021031120210329.html